专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09399091B2 System and method to regulate ultrafiltration 有权
标题翻译：调节超滤的系统和方法
公开(公告)号：US09399091B2
公开(公告)日：2016-07-26
申请号：US12571127
申请日：2009-09-30
申请人： Daniel C. Sigg , Sarah Anne Audet , Tommy D. Bennett , Dwight H. Warkentin
发明人： Daniel C. Sigg , Sarah Anne Audet , Tommy D. Bennett , Dwight H. Warkentin
IPC分类号： A61M37/00 , A61M1/34 , A61M1/16 , A61M1/36
CPC分类号： A61M1/3403 , A61M1/16 , A61M1/34 , A61M1/3406 , A61M1/341 , A61M1/36 , A61M1/3669 , A61M2205/18 , A61M2205/33 , A61M2205/3334 , A61M2205/3344 , A61M2205/3523 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2230/005 , A61M2230/04 , A61M2230/20 , A61M2230/201 , A61M2230/30 , A61M2230/65
摘要： A medical device system including a physiological sensor and ultrafiltration unit senses a physiological signal in a patient and computes a fluid status measurement of the patient using the physiological signal. Ultrafiltration therapy is delivered to the patient according to a therapy delivery control parameter established in response to the fluid status measurement.
摘要翻译：包括生理传感器和超滤单元的医疗装置系统感测患者的生理信号，并使用生理信号计算患者的流体状况测量。根据响应于流体状态测量而建立的治疗递送控制参数将超滤治疗递送给患者。

2. 发明申请

US20110077574A1 SYSTEM AND METHOD TO REGULATE ULTRAFILTRATION 有权
标题翻译：用于调节超滤的系统和方法
公开(公告)号：US20110077574A1
公开(公告)日：2011-03-31
申请号：US12571127
申请日：2009-09-30
申请人： Daniel C. Sigg , Sarah Anne Audet , Tommy D. Bennett , Dwight H. Warkentin
发明人： Daniel C. Sigg , Sarah Anne Audet , Tommy D. Bennett , Dwight H. Warkentin
IPC分类号： A61M1/36
CPC分类号： A61M1/3403 , A61M1/16 , A61M1/34 , A61M1/3406 , A61M1/341 , A61M1/36 , A61M1/3669 , A61M2205/18 , A61M2205/33 , A61M2205/3334 , A61M2205/3344 , A61M2205/3523 , A61M2205/50 , A61M2205/502 , A61M2205/52 , A61M2230/005 , A61M2230/04 , A61M2230/20 , A61M2230/201 , A61M2230/30 , A61M2230/65
摘要： A medical device system including a physiological sensor and ultrafiltration unit senses a physiological signal in a patient and computes a fluid status measurement of the patient using the physiological signal. Ultrafiltration therapy is delivered to the patient according to a therapy delivery control parameter established in response to the fluid status measurement.
摘要翻译：包括生理传感器和超滤单元的医疗装置系统感测患者的生理信号，并使用生理信号计算患者的流体状况测量。根据响应于流体状态测量而建立的治疗递送控制参数将超滤治疗递送给患者。

3. 发明申请

US20100016740A1 CARDIAC PROTECTION SYSTEM AND METHOD 有权
标题翻译：心脏保护系统和方法
公开(公告)号：US20100016740A1
公开(公告)日：2010-01-21
申请号：US12173780
申请日：2008-07-15
申请人： Daniel C. Sigg , James A. Coles, JR. , Dwight H. Warkentin , Deborah Ann Jaye
发明人： Daniel C. Sigg , James A. Coles, JR. , Dwight H. Warkentin , Deborah Ann Jaye
IPC分类号： A61B5/02 , A61N1/00
CPC分类号： A61N1/365 , A61B5/0031 , A61N1/368 , A61N1/3702 , A61N1/37258 , A61N1/37282 , A61N1/37288
摘要： A cardiac ischemic protection system and method for conditioning a patient's heart is provided. The method can include detecting acute myocardial infarction, angina pectoris, silent ischemia, or stunning and providing closed-loop dyssynchronous pacing to the patient's heart to precondition and/or postcondition the patient's heart in order to reduce ischemic damage.
摘要翻译：提供了用于调节患者心脏的心脏缺血保护系统和方法。该方法可以包括检测急性心肌梗塞，心绞痛，静息缺血或惊恐，并向患者的心脏提供闭环异步起搏以预先和/或后置病人的心脏以减少缺血性损伤。

4. 发明授权

US08126549B2 Cardiac protection system and method 有权
标题翻译：心脏保护系统及方法
公开(公告)号：US08126549B2
公开(公告)日：2012-02-28
申请号：US12173780
申请日：2008-07-15
申请人： Daniel C. Sigg , James A. Coles, Jr. , Dwight H. Warkentin , Deborah Ann Jaye
发明人： Daniel C. Sigg , James A. Coles, Jr. , Dwight H. Warkentin , Deborah Ann Jaye
IPC分类号： A61N1/362
CPC分类号： A61N1/365 , A61B5/0031 , A61N1/368 , A61N1/3702 , A61N1/37258 , A61N1/37282 , A61N1/37288
摘要： A cardiac ischemic protection system and method for conditioning a patient's heart is provided. The method can include detecting acute myocardial infarction, angina pectoris, silent ischemia, or stunning and providing closed-loop dyssynchronous pacing to the patient's heart to precondition and/or postcondition the patient's heart in order to reduce ischemic damage.
摘要翻译：提供了用于调节患者心脏的心脏缺血保护系统和方法。该方法可以包括检测急性心肌梗塞，心绞痛，静息缺血或惊恐，并向患者的心脏提供闭环异步起搏以预先和/或后置病人的心脏以减少缺血性损伤。

5. 发明授权

US08565898B2 Rate control during AF using cellular intervention to modulate AV node 有权
标题翻译：使用细胞干预调整AV节点的AF期间的速率控制
公开(公告)号：US08565898B2
公开(公告)日：2013-10-22
申请号：US11116621
申请日：2005-04-28
申请人： Vinod Sharma , Daniel C. Sigg
发明人： Vinod Sharma , Daniel C. Sigg
IPC分类号： A61N1/00 , A61K38/00 , A61K38/16
CPC分类号： A61N1/362 , A61K9/0019 , A61K31/221 , A61K38/177 , A61N1/0568
摘要： A biologic intervention method and apparatus generates a persistent modification to an AV node that is physiologically stable after the agent has matured but is alterable with subsequent application of an agent. Specifically, the generic agent is used to modulate a node in a cardiac conduction system including rate control using one and a combination of a family of K+ channel or equivalent. Specifically, the channel is implemented to slow conduction by generating an outward current during optimization of action potential and repolarization phase thus decreasing the current that is available to excite downstream cells. A Kv 1.3 channel, for example, may be used as the biologic channel. The invention enables reversal of the modulation or adjustment for various heart rates (BPM) based on medical and patient-specific needs.
摘要翻译：生物干预方法和装置对于在该药剂已经成熟但随后随后施用药剂而可变化的生理稳定的AV节点产生持久性修饰。具体地，通用代理用于调制心脏传导系统中的节点，包括使用一个K +通道或等效物系的组合的速率控制。具体地，通过在动作电位和复极相优化期间产生向外的电流来实现缓慢传导，从而减少可用于激发下游单元的电流。例如，可以使用Kv1.3通道作为生物通道。本发明能够根据医疗和患者特定的需要逆转各种心率（BPM）的调节或调整。

6. 发明申请

US20100274221A1 PRESSURE MONITORING TO CONTROL DELIVERY OF THERAPEUTIC AGENT 有权
标题翻译：压力监测控制治疗药物的输送
公开(公告)号：US20100274221A1
公开(公告)日：2010-10-28
申请号：US12767224
申请日：2010-04-26
申请人： Daniel C. Sigg , Prasanga D. Hiniduma-Lokuge , Mary M. Morris
发明人： Daniel C. Sigg , Prasanga D. Hiniduma-Lokuge , Mary M. Morris
IPC分类号： A61M5/172 , A61B5/03
CPC分类号： A61B5/036 , A61B5/0031 , A61B5/0215 , A61B5/4839 , A61M5/14276 , A61M5/16854 , A61M5/1723 , A61M2005/1726 , A61M2205/3331 , A61M2205/3334
摘要： A method for adjusting delivery of a therapeutic fluid to a patient suffering from or at risk of pulmonary arterial hypertension includes introducing the therapeutic fluid to a patient via a catheter at a predetermined rate. The catheter is positioned to deliver the fluid to the right ventricle or the pulmonary artery. The catheter a one-way valve configured to allow the fluid to flow from the catheter to the target location. The method further includes monitoring pressure of the target location by monitoring internal catheter pressure, and adjusting the rate at which the therapeutic fluid is introduced to the catheter based on the monitored pressure. The rate at which the fluid is introduced to the catheter is increased if internal catheter pressure increases, and the rate at which the fluid is introduced to the catheter is decreased if the internal catheter pressure decreases.
摘要翻译：用于调节对患有或具有肺动脉高压的风险的患者的治疗流体的递送的方法包括以预定的速率经由导管将治疗流体引入患者体内。定位导管以将流体输送到右心室或肺动脉。导管是单向阀，其构造成允许流体从导管流到目标位置。该方法还包括通过监测内部导管压力来监测目标位置的压力，并且基于所监测的压力来调节治疗流体被引入导管的速率。如果内部导管压力增加，流体被引入导管的速率增加，并且如果内部导管压力降低，则将流体引入导管的速率降低。

7. 发明授权

US08892197B2 Method and apparatus to control conduction through the heart to treat cardiac conditions 有权
标题翻译：控制心脏传导以治疗心脏病症的方法和装置
公开(公告)号：US08892197B2
公开(公告)日：2014-11-18
申请号：US11192884
申请日：2005-07-29
申请人： Michael R. Ujhelyi , Daniel C. Sigg
发明人： Michael R. Ujhelyi , Daniel C. Sigg
IPC分类号： A61B5/04 , A61M31/00 , A61M5/142 , A61N1/05 , A61M5/172 , A61N1/365
CPC分类号： A61M5/1723 , A61B5/046 , A61M5/14276 , A61M2005/1726 , A61M2210/125 , A61M2230/04 , A61M2230/63 , A61N1/0575 , A61N1/365 , A61N1/3682
摘要： Control of conduction through a heart is described. A lead with a proximal end and a distal end is provided. The distal end of the lead is inserted into a target area. An agent is delivered through the lead to the target area. Delivery of the agent is monitored via a closed loop feedback system.
摘要翻译：描述通过心脏传导的控制。提供具有近端和远端的引线。引线的远端插入目标区域。代理商通过领导交付给目标地区。通过闭环反馈系统监控代理的交付。

8. 发明申请

US20120035587A1 METHODS AND SYSTEMS FOR PROVIDING THERAPIES INTO THE PERICARDIAL SPACE 有权
标题翻译：将治疗提供给心脏空间的方法和系统
公开(公告)号：US20120035587A1
公开(公告)日：2012-02-09
申请号：US13273521
申请日：2011-10-14
申请人： Daniel C. Sigg , Michael R. Ujhelyi , Mary M. Morris
发明人： Daniel C. Sigg , Michael R. Ujhelyi , Mary M. Morris
IPC分类号： A61M5/168 , A61M5/142
CPC分类号： A61M5/14276 , A61B17/00234 , A61B17/3417 , A61B17/3478 , A61B18/1492 , A61B2017/00247 , A61B2017/003 , A61B2017/22077 , A61B2017/3484 , A61B2017/3488 , A61B2017/349 , A61B2018/00291 , A61B2018/00357 , A61B2018/00392 , A61M5/1723 , A61M2005/1405 , A61M2205/3523
摘要： Methods and systems for transvenously accessing the pericardial space via the vascular system and atrial wall, particularly through the superior vena cava and right atrial wall, to deliver a pharmacologic agent, particularly a NO-donor drug, to the heart are disclosed. A proximal connector of an infusion catheter is coupled to an infusion pump, and a distal catheter segment having a distal infusion catheter lumen end opening is disposed in the pericardial space. The implantable infusion pump is operable in conjunction with an implantable ischemia monitor to monitor the ischemic state and trigger delivery or regulate the periodic delivery of the pharmacologic agent to optimally treat ischemia. The patient may operate a patient activator that the patient when feeling ischemia symptoms to transmit a signal that is received by the implantable infusion pump and triggers delivery of a bolus and/or continuous infusion.
摘要翻译：公开了通过血管系统和心房壁，特别是通过上腔静脉和右心房壁经心脏进入心包空间的方法和系统，以向心脏递送药理学特别是NO供体药物。输注导管的近端连接器联接到输注泵，并且具有远端输注导管腔端部开口的远侧导管段设置在心包空间中。可植入输注泵可与可植入缺血监测器结合操作以监测缺血状态并触发递送或调节药理学剂的周期性递送以最佳地治疗缺血。患者可以操作患者活化剂，当感觉到缺血症状时患者传递由可植入输液泵接收的信号并触发推注和/或连续输注的传递。

9. 发明授权

US07390311B2 Delivery of a sympatholytic cardiovascular agent to the central nervous system 有权
标题翻译：交配性心血管药物向中枢神经系统递送
公开(公告)号：US07390311B2
公开(公告)日：2008-06-24
申请号：US10903599
申请日：2004-07-30
申请人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
发明人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
IPC分类号： A61M31/00
CPC分类号： A61M5/142 , A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3523 , A61M2230/00 , A61M2230/04 , A61M2230/63 , A61N1/3962
摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
摘要翻译：由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西汀，脱甲基丸，美托咪定和右美托咪定）。

10. 发明授权

US08348884B2 Delivery of a sympatholytic cardiovascular agent to the central nervous system 有权
标题翻译：交配性心血管药物向中枢神经系统递送
公开(公告)号：US08348884B2
公开(公告)日：2013-01-08
申请号：US12128046
申请日：2008-05-28
申请人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
发明人： Keith R. Hildebrand , Michael R. Ujhelyi , Xiaohong Zhou , Daniel C. Sigg , Linda M. Page
IPC分类号： A61M31/00
CPC分类号： A61M5/142 , A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3523 , A61M2230/00 , A61M2230/04 , A61M2230/63 , A61N1/3962
摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).
摘要翻译：由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解急性或慢性心脏损伤或心脏功能受损的症状。药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与心脏损伤相关的生理参数或心脏功能受损并触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。交感神经心血管药物是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂（例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫索尼定，甲基多巴，甲苯噻嗪，胍法西汀，脱甲基丸，美托咪定和右美托咪定）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式